OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases and develop new antibody linker ...

STOCKHOLM, SE / ACCESS Newswire / April 23, 2025 / Vicore Pharma Holding (STO:VICO)Stockholm, April 23, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two oral presentations and a poster presentation featuring data for the company’s NeXT ...

Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, ...

CAMBRIDGE, Mass., April 22, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today ...

NeoGenomics, Inc. ("NeoGenomics" or the "Company") , a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBxtm assay, a next-generation ...

The Summit brings together Fortune 500 leaders, entrepreneurs, and sustainability experts to create a more vibrant, equitable ...

I am excited to update you on our overall strategy, progress, and key priorities and goals for 2025. Strategic Overview and ...

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

Data From GRAIL's ctDNA-based Targeted Methylation Assay Highlight Potential to Identify Robust Signals of Promoter Methylation MENLO PARK, Calif., April 22, 2025 /PRNewswire/ -- ...